Inhalants: The Substance Class Nobody Talks About
Legal, cheap, and lethal on the first use. Underappreciated in addiction education — especially for kids.
Body — 8 lenses: [Science: solvents act as NMDA antagonists + GABA modulators; nitrites as smooth-muscle relaxants via NO; aerosols variable. Biology: sudden sniffing death syndrome (cardiac sensitization to catecholamines), hypoxia, leukoencephalopathy (toluene), hepatorenal toxicity. Psychology: typically first-used age 9–13, often precedes other substance use; associated with ACEs. Policy: mostly not controlled (volatile solvents legal); age-of-sale laws for specific products; poppers under ambiguous FDA status. Trends: SAMHSA NSDUH tracks; resurgence concerns in some regions. Social: historically framed as “kid’s drug”; underrepresented in most SUD curricula. Treatment: abstinence-based (no meds); family therapy; CRAFT. Harm reduction: never use alone, ventilation, don’t use with CNS depressants, education for parents and schools.]
Sources Cited
- 01.A
- 02.A
Filed Under
sciencebiologypsychologypolicytrendssocial-culturaltreatmentharm-reductionYouth & Young AdultsFamilies & CaregiversPeer-Reviewed Research
Keep up with the reporting.
One email each morning with the stories that put days like this in context.
Continue reading
More from this section
Dispensary Weed Is a Different Drug Than the One D.A.R.E. Warned You About
Dispensary THC now routinely exceeds 40%, quadruple 1995 levels. The addiction and psychosis science on high-potency cannabis is real, dose-dependent, and almost nobody at the counter has to mention it.
Science & MedicineThe Overdose Charts Miss This: A Decade of Data Says a Third of Alcohol-Induced Crises Come With Depression Attached
A decade of federal treatment data finds alcohol- and substance-induced psychiatric disorders are rare in raw numbers but frequently paired with depression — a screening gap most facilities aren't built to catch.
Science & MedicineEvery Two Years, the Fake Xanax Gets a New Name. The Real Trend Is the Naming Pattern Itself.
Bromazolam is the fourth designer benzodiazepine sold as counterfeit Xanax since 2020. The DEA keeps scheduling the newest one — the trend data says that's not where the problem lives.